Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases. Its lead product candidate is ASN100, a mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia in mechanically ventilated patients. The company's preclinical pipeline comprises mAbs targeting various bacterial and viral pathogens, including respiratory syncytial virus. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone781-819-5704
Debt
Current Ratio5.08
Quick Ratio5.08
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Price / Cash FlowN/A
Price / Book0.77
Profitability
Net Income$-33,870,000.00
Net MarginsN/A
Return on Assets-70.75%
Miscellaneous
Employees40
OptionableNot Optionable
Arsanis (NASDAQ:ASNS) Frequently Asked Questions
What is Arsanis' stock symbol?
Arsanis trades on the NASDAQ under the ticker symbol "ASNS."
How were Arsanis' earnings last quarter?
Arsanis Inc (NASDAQ:ASNS) posted its quarterly earnings results on Friday, November, 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.74) by $0.02. View Arsanis' Earnings History.
When is Arsanis' next earnings date?
What price target have analysts set for ASNS?
4 Wall Street analysts have issued 12-month price objectives for Arsanis' stock. Their forecasts range from $2.50 to $26.00. On average, they anticipate Arsanis' stock price to reach $14.25 in the next year. This suggests a possible upside of 331.8% from the stock's current price. View Analyst Price Targets for Arsanis.
What is the consensus analysts' recommendation for Arsanis?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arsanis in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Arsanis.
What are Wall Street analysts saying about Arsanis stock?
Here are some recent quotes from research analysts about Arsanis stock:
- 1. According to Zacks Investment Research, "Arsanis, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovering and developing monoclonal antibodies for the targeted immunotherapy of serious infections. The company's product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500 which are in preclinical stage. It operates primarily in the United States and Austria. Arsanis, Inc. is based in Waltham, United States. " (11/14/2018)
- 2. Cantor Fitzgerald analysts commented, "As the company advances its pipeline toward commercialization, we expect catalysts to drive Arsanis’s stock higher. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our $26 12-month price target. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of EV/EBITDA and DCF analysis to arrive at our $26 12-month price target." (6/28/2018)
Has Arsanis been receiving favorable news coverage?
News articles about ASNS stock have been trending negative on Wednesday, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Arsanis earned a news sentiment score of -2.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the stock's share price in the near term.
Are investors shorting Arsanis?
Arsanis saw a drop in short interest in December. As of December 14th, there was short interest totalling 578,950 shares, a drop of 50.7% from the November 30th total of 1,173,598 shares. Based on an average daily trading volume, of 2,199,226 shares, the days-to-cover ratio is presently 0.3 days. View Arsanis' Current Options Chain.
Who are some of Arsanis' key competitors?
Some companies that are related to Arsanis include LogicBio Therapeutics (LOGC), Allena Pharmaceuticals (ALNA), La Jolla Pharmaceutical (LJPC), Jounce Therapeutics (JNCE), ADMA Biologics (ADMA), Neon Therapeutics (NTGN), Compugen (CGEN), Erytech Pharma (ERYP), Fennec Pharmaceuticals (FENC), Surface Oncology (SURF), Organovo (ONVO), Pluristem Therapeutics (PSTI), Nantkwest (NK), Champions Oncology (CSBR) and Idera Pharmaceuticals (IDRA).
Who are Arsanis' key executives?
Arsanis' management team includes the folowing people:
- Dr. Tillman U. Gerngross, Co-Founder & Chairman (Age 55)
- Mr. Michael P. Gray CPA, M.B.A., MBA, CPA, Pres, CEO & CFO (Age 48)
- Dr. Anthony Christopher Stevens, Chief Medical Officer (Age 60)
- Dr. Eszter Nagy, Co-Founder (Age 53)
- Mr. David S. Mantus, Chief Devel. Officer (Age 56)
When did Arsanis IPO?
(ASNS) raised $50 million in an IPO on Thursday, November 16th 2017. The company issued 3,100,000 shares at $15.00-$17.00 per share. Citigroup, Cowen and Piper Jaffray acted as the underwriters for the IPO.
How do I buy shares of Arsanis?
Shares of ASNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arsanis' stock price today?
One share of ASNS stock can currently be purchased for approximately $3.30.
How big of a company is Arsanis?
Arsanis has a market capitalization of $50.25 million. The company earns $-33,870,000.00 in net income (profit) each year or ($16.23) on an earnings per share basis. Arsanis employs 40 workers across the globe.
What is Arsanis' official website?
How can I contact Arsanis?
Arsanis' mailing address is 890 WINTER STREET SUITE 230, WALTHAM MA, 02451. The company can be reached via phone at 781-819-5704 or via email at [email protected]
MarketBeat Community Rating for Arsanis (NASDAQ ASNS)
MarketBeat's community ratings are surveys of what our community members think about Arsanis and other stocks. Vote "Outperform" if you believe ASNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASNS will underperform the S&P 500 over the long term. You may vote once every thirty days.
